The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
A meeting on lymphoma Biology by the American Society of Hematology (ASH) took place between 2–5 August 2018, in Chantilly, Virginia. The program was ACCME-accredited and featured a variety of sessions for experts to discuss the unmet needs in the lymphoma community.
Dr Francesc Bosch, University Hospital Vall d’Hebron, Barcelona, is a member of the Lymphoma Hub scientific advisory board and who attended the meeting in August. Dr Bosch provided a summary of the meeting for the Lymphoma Hub capturing the key outcomes of what was discussed.
Expert Opinion
New technologies: histo-cytometry tech data and data on circulating tumoral DNA was found to be useful for analysis of resistant clones, genotyping tutors, and analysis of the dynamics of ctDNA during treatment, becoming a reliable early (after 2nd cycle) predictor of response to therapy
Targeting therapies: Anthony Letai, discussed potential combinations that increase BCL2 dependency of the tumoral cells, (i.e., adding bortezomib or Azacitidine). Margaret Shipp and Louis Staudt presented the data of the classification of lymphomas based on the gene expression profile and the presence of genetic lesions. These new five subgroups could be of paramount relevance when deciding therapies. Bertrand Nadel presented a comprehensive analysis of single cell RNAseq of normal germinal center cells and follicular lymphomas, demonstrating that there is an enormous inter-patient variation and important intra-patient heterogeneity
Ralf Kuppers presented data on the normal CD30+ cells inside and outside germinal center, and finally, Elias Campo revised the recent data on the activity of Cyclin D1 in the pathogenesis of mantle cell lymphoma
Francesc Bosch